Terms: = Ovarian cancer AND uPA
197 results:
1. ALG3 Promotes Peritoneal Metastasis of ovarian cancer through Increasing Interaction of α1,3-mannosylated upaR and ADAM8.
Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
[TBL] [Abstract] [Full Text] [Related]
2. Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Shahdeo D; Kesarwani V; Suhag D; Ahmed J; Alshehri SM; Gandhi S
Carbohydr Polym; 2021 Aug; 266():118138. PubMed ID: 34044952
[TBL] [Abstract] [Full Text] [Related]
3. Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression.
Wang JJ; Siu MK; Jiang YX; Chan DW; Cheung AN; Ngan HY; Chan KK
Cancer Immunol Immunother; 2020 Nov; 69(11):2275-2289. PubMed ID: 32504248
[TBL] [Abstract] [Full Text] [Related]
4. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract] [Full Text] [Related]
5. Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis.
Ghasemi A; Saeidi J; Mohtashami M; Hashemy SI
Mol Cell Biochem; 2019 Aug; 458(1-2):207-217. PubMed ID: 31077012
[TBL] [Abstract] [Full Text] [Related]
6. Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic upa-derived peptide: first in vitro evaluations.
Wacker A; Bauder-Wüst U; Schäfer M; Schmidt J; Remde Y; Stadlbauer S; Eder M; Liolios C; Kopka K
J Labelled Comp Radiopharm; 2019 Jun; 62(8):483-494. PubMed ID: 30970388
[TBL] [Abstract] [Full Text] [Related]
7. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract] [Full Text] [Related]
8. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
[TBL] [Abstract] [Full Text] [Related]
9. Downregulation of SPINK13 Promotes Metastasis by Regulating upa in ovarian cancer Cells.
Cai S; Zhang P; Dong S; Li L; Cai J; Xu M
Cell Physiol Biochem; 2018; 45(3):1061-1071. PubMed ID: 29439245
[TBL] [Abstract] [Full Text] [Related]
10. 3,4',7-O-trimethylquercetin Inhibits Invasion and Migration of ovarian cancer Cells.
Yamauchi K; Afroze SH; Mitsunaga T; McCormick TC; Kuehl TJ; Zawieja DC; Uddin MN
Anticancer Res; 2017 Jun; 37(6):2823-2829. PubMed ID: 28551617
[TBL] [Abstract] [Full Text] [Related]
11. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M; Sabourinejad Z; Zarrinrad G; Moghaddaskho F; Eyvani H; Yousefi H; Mirshahvaladi S; Poursani EM; Barghi F; Poursheikhani A; Dardaei L; Bashash D; Ghazi-Khansari M; Tavangar SM; Dehpour AR; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Apr; 7():45954. PubMed ID: 28383032
[TBL] [Abstract] [Full Text] [Related]
12. RhoA/ROCK pathway mediates leptin-induced upa expression to promote cell invasion in ovarian cancer cells.
Ghasemi A; Hashemy SI; Aghaei M; Panjehpour M
Cell Signal; 2017 Apr; 32():104-114. PubMed ID: 28104444
[TBL] [Abstract] [Full Text] [Related]
13. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
[TBL] [Abstract] [Full Text] [Related]
14. ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
[TBL] [Abstract] [Full Text] [Related]
15. Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.
Mikuła-Pietrasik J; Uruski P; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Med Oncol; 2016 Aug; 33(8):94. PubMed ID: 27431203
[TBL] [Abstract] [Full Text] [Related]
16. Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions.
Pei H; Yang Y; Cui L; Yang J; Li X; Yang Y; Duan H
Sci Rep; 2016 Jun; 6():28773. PubMed ID: 27349797
[TBL] [Abstract] [Full Text] [Related]
17. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract] [Full Text] [Related]
18. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
[TBL] [Abstract] [Full Text] [Related]
19. A novel upag-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitro.
Zhao LP; Xu TM; Kan MJ; Xiao YC; Cui MH
Int J Mol Med; 2016 May; 37(5):1310-6. PubMed ID: 27035617
[TBL] [Abstract] [Full Text] [Related]
20. cRGD inhibits vasculogenic mimicry formation by down-regulating upa expression and reducing EMT in ovarian cancer.
Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
[TBL] [Abstract] [Full Text] [Related]
[Next]
